• Research in the Ramesh Laboratory in the Center for Genomic Medicine focused on Tuberous Sclerosis Complex (TSC), Neurofibromatosis Type 2 (NF2), and mTOR signaling pathway• Upcoming publication: Alteration in mRNA translation of Tuberous Sclerosis Complex patient-derived neural progenitor cells is only partially reversed by rapamycin• Used patient-derived isogenic CRISPR neural progenitor cell model to examine early neurodevelopmental aspects of TSC disorder• Tested efficacy of novel therapeutic compounds on cell viability/proliferation (by in vitro drug screen and dose response curve generation), mTOR signaling pathway (by western blot), and cell morphology (by immunocytochemistry)• Presented data at weekly lab meetings, reviewed latest literature in the field